Regulatory news · EU regulation

EMA consults on revising the Guideline on Risk Assessment of Medicinal Products in Human Reproduction & Breastfeeding

Officials sitting around a table in glass-fronted modern office high up in a tall building.

This draft guidance, once adopted sometime in mid-2027, will replace “Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling (EMEA/CHMP/203927/2005)”.

The main aim of this revision was to reflect current standards regarding non-clinical - including the option for new approach methods (NAMs) - and clinical assessments.

Sources

  1. Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information. EMA, Europe. Published .
  2. EU Survey Form.

This article is for general information. It is not legal, clinical or regulatory advice.

Back to all news